Artelo Biosciences (ARTL) Total Liabilities (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Total Liabilities of $4.1 million for Q4 2025, up 121.24% year-over-year from $1.8 million in Q4 2024, and down 16.88% quarter-over-quarter from $4.9 million in Q3 2025.
Artelo Biosciences (ARTL) Total Liabilities (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Total Liabilities for 12 consecutive years, with $4.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 121.24% year-over-year to $4.1 million; the TTM figure through Dec 2025 stood at $4.1 million (up 121.24% YoY), while the FY2025 annual figure was $4.1 million, up 121.24% from the prior year.
- Total Liabilities fell to $4.1 million in Q4 2025 per ARTL's latest filing, from $4.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $13.4 million in Q1 2021 and bottomed at $512000.0 in Q3 2022.
- Historically, Total Liabilities has averaged $2.8 million across 5 years, with a median of $972500.0 in 2022.
- Annual changes were most pronounced in 2021 — Total Liabilities tumbled 92.47% — and 2025, when it surged 532.26%.
- Artelo Biosciences' Total Liabilities stood at $718000.0 in 2021, then soared by 42.2% to $1.0 million in 2022, then gained by 26.44% to $1.3 million in 2023, then jumped by 42.6% to $1.8 million in 2024, then surged by 121.24% to $4.1 million in 2025.
- Business Quant data shows ARTL's Total Liabilities at $4.1 million in Q4 2025, $4.9 million in Q3 2025, and $5.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 10.03 Bn |
| 10 | Artelo Biosciences | 113,758.27 | -486,241.73 | - | 4.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | 4.90 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | 775,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 817,000.00 |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 921,000.00 |
| Jun 30, 2023 | 609,000.00 |
| Mar 31, 2023 | 840,000.00 |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 512,000.00 |
| Jun 30, 2022 | 567,000.00 |
| Mar 31, 2022 | 924,000.00 |
| Nov 30, 2021 | 718,000.00 |
| Aug 31, 2021 | 593,000.00 |
| May 31, 2021 | 12.34 Mn |
| Feb 28, 2021 | 13.44 Mn |